Related references
Note: Only part of the references are listed.An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui-Ru Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
Zahra Hanaizi et al.
EUROPEAN JOURNAL OF CANCER (2012)
Polymorphisms in the Cytotoxic T-Lymphocyte Antigen 4 Gene and Cancer Risk
Yonggang Zhang et al.
CANCER (2011)
T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma
Michele Del Vecchio et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Atypical Clinical Response Patterns to Ipilimumab: Four Case Studies of Advanced Melanoma
Blanca Ledezma et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2011)
CTLA-4+49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence
Patrizia Piccioli et al.
ANNALS OF HEMATOLOGY (2010)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
Ahmad Tarhini et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
Marna G. Bouwhuis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies
Annalisa Brozzetti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers
David B. Page et al.
IMMUNOTHERAPY (2010)
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
Helen Gogas et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anti-CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
Margaret K. Callahan et al.
SEMINARS IN ONCOLOGY (2010)
Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies
Santiago Rodriguez et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2009)
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Jeffrey Weber
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Genetic Polymorphisms in Cytotoxic T-Lymphocyte Antigen 4 and Cancer: The Dialectical Nature of Subtle Human Immune Dysregulation
Tong Sun et al.
CANCER RESEARCH (2009)
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
Antoni Ribas et al.
CLINICAL CANCER RESEARCH (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer
Tong Sun et al.
CANCER RESEARCH (2008)
Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers
Ahmad A. Tarhini et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade
Willemijn B. Breunis et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Genomic regulation of CTLA4 and Multiple Sclerosis
Ricardo Palacios et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
Chrysoula I. Liakou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Hexaprimer amplification refractory mutation system PCR for simultaneous single-tube genotyping of 2 close polymorphisms
Patrizia Piccioli et al.
CLINICAL CHEMISTRY (2008)
Association of-318 C/T and+49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis
G. Balbi et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
KS Peggs et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade
AV Maker et al.
JOURNAL OF IMMUNOLOGY (2005)
The polymorphisms -318C>T in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian population
J Svahn et al.
BONE MARROW TRANSPLANTATION (2005)
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
H Ueda et al.
NATURE (2003)
A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele
S Anjos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
A CTLA-4 gene polymorphism at position-318 in the promoter region affects the expression of protein
XB Wang et al.
GENES AND IMMUNITY (2002)
Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease
MK Oaks et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
